evolocumab (repatha) Report issue

Biologics mAb Orphan Drug FDA Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH repoDB

Active Ingredient History

NOW
  • Now
Evolocumab, sold under the brand name Repatha, is a monoclonal antibody that is an immunotherapy medication for the treatment of hyperlipidemia.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$181.1954 - $392.8910

United States

$182.1100 - $230.2174
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

amg 145 | amg-145 | evolocumab | repatha | repatha sureclick

Organizations (94)

Research & Development (94)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (51)

Approved Indications (2)


 

Coronary Artery Disease

Hyperlipoproteinemia Type II

Experimental Indications - Clinical Trial Phases 1-4 (51)


 

Acute Coronary Syndrome (Phase 4)

Aortic Aneurysm, Abdominal (Early Phase 1)

Aortic Valve Stenosis (Phase 3)

Arterial Occlusive Diseases (Phase 4)

Atherosclerosis (Phase 4)

Cardiovascular Diseases (Phase 4)

Carotid Artery Diseases (Phase 4)

Carotid Stenosis (Phase 4)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 4)

Chronic Limb-Threatening Ischemia (Phase 4)

Clinical Trial (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

COVID-19 (Phase 3)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Dyslipidemias (Phase 4)

General Surgery (Phase 4)

Glioblastoma (Early Phase 1)

Glioma (Early Phase 1)

Healthy Volunteers (Phase 1)

Heart Diseases (Phase 4)

Heart Failure, Systolic (Phase 2)

Heart Transplantation (Phase 2)

HIV (Phase 2)

HIV Infections (Phase 3)

Homozygous Familial Hypercholesterolemia (Phase 4)

Hypercholesterolemia (Phase 4)

Hyperlipidemias (Phase 4)

Hyperlipoproteinemia Type II ()

Hyperlipoproteinemia Type III (Phase 4)

Hypertension (Phase 4)

Inflammation (Phase 4)

Intracranial Arteriosclerosis (Phase 4)

Ischemic Stroke (Phase 4)

Lipoproteins (Phase 4)

Livedoid Vasculopathy (Phase 3)

Lung Neoplasms (Phase 2)

Muscle Spasticity (Phase 1/Phase 2)

Myocardial Infarction (Phase 4)

Neoplasms (Phase 4)

Percutaneous Coronary Intervention (Early Phase 1)

Peripheral Arterial Disease (Phase 4)

Pharmacokinetics (Phase 1)

Renal Insufficiency, Chronic (Phase 4)

Sepsis (Phase 2)

ST Elevation Myocardial Infarction (Phase 4)

Stroke (Phase 4)

Subtilisin (Phase 4)

Vascular Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 111
  • # of Trial Organizations: 94

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue